NewAmsterdam Pharma (NAMS) is a clinical-stage biopharmaceutical company that develops oral and non-satin medicines for patients at high risk of cardiovascular disease. CEO, Dr. Michael Davidson joins Nicole Petallides to discuss NAMS. He talks about how NAMS announced encouraging data from a phase 2 trial of high cholesterol treatment. He also goes over how NAMS is up over 60% year-to-date. Tune in to find out more about the stock market today.
31 Jan 2023
The Watch List
22 Jan 2023
The Watch List
17 Feb 2023
Market On Close
23 Jan 2023
Morning Trade Live
23 Jan 2023
Market On Close
24 Feb 2023